Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 1,500 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $142.18, for a total transaction of $213,270.00. Following the sale, the executive vice president now owns 26,571 shares in the company, valued at $3,777,864.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Michael Patrick Miller also recently made the following trade(s):
- On Monday, January 13th, Michael Patrick Miller sold 1,500 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $146.78, for a total transaction of $220,170.00.
- On Monday, December 9th, Michael Patrick Miller sold 1,500 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $149.12, for a total transaction of $223,680.00.
JAZZ stock opened at $140.85 on Friday. The company’s 50 day moving average price is $146.52 and its 200 day moving average price is $137.40. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.71 and a current ratio of 3.89. Jazz Pharmaceuticals PLC has a fifty-two week low of $116.52 and a fifty-two week high of $154.24. The firm has a market capitalization of $8.03 billion, a price-to-earnings ratio of 10.26, a PEG ratio of 0.76 and a beta of 1.18.
A number of analysts have issued reports on JAZZ shares. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, November 29th. Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, January 8th. They set a “neutral” rating and a $153.00 price target on the stock. ValuEngine lowered shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 15th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Co boosted their price target on shares of Jazz Pharmaceuticals from $186.00 to $189.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Jazz Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $166.14.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Story: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.